Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chinese Journal of Cancer》 2007-08
Add to Favorite Get Latest Update

Efficacy of Transcatheter Arterial Chemoembolization Combined Thalidomide on Hepatocellular Carcinoma: A Controlled Randomized Trial

HAO Ming-Zhi1, LIN Hai-Lan1, CHEN Qiang2, WU Hui2, YU Wen-Chang1, CHEN Tang-Geng1 1. Department of Interventional Radiology, Fujian Provincial Tumor Hospital, Fuzhou, Fujian, 350014, P. R. China 2. Department of Medical Oncology, Fujian Provincial Tumor Hospital, Fuzhou, Fujian, 350014, P. R. China  
BACKGROUND OBJECTIVE: Transcatheter arterial chemoembolization (TACE) is an important therapy for hepatocellular carcinoma (HCC), but the recurrence rate is still high and the long-term survival is unsatisfactory. This study was to evaluate the efficacy of TACE combined thalidomide on HCC. METHODS: From Aug. 2004 to Aug. 2006, 108 patients with unresectable primary HCC were randomized into combination (TACE plus thalidomide) group and TACE group. Combination group received oral administration of thalidomide (200 mg/d) for 1-6 months. Both groups were treated with 0.4-1.6 g gemcitabine, 100-200 mg oxaliplatin, and 0.5-1.0 g floxuridine as chemotherapeutic drugs, ethanol, glutin, and iodolipol as ambolic agent in TACE. The side effects of thalidomide and survival of the patients were observed. RESULTS: The median survival period was 18 months [95% confidence interval (CI), 12-24 months] in combination group and 13 months (95% CI, 10-16 months) in TACE group. The 6-month, 1-year, and 2- year survival rates were 92.9%, 82.7%, and 58.4% respectively in combination group, and 85.6%, 57.2%, and 32.3% respectively in TACE group. The median time to progression was significantly longer in combination group than in TACE group [181 days (95% CI, 91-271 days) vs. 97 days (95% CI, 33-161 days), P0.05]. Excluding the patients who took thalidomide for less than 1 month, the median survival period was significantly longer in combination group than in TACE group [18 months (95% CI, 12-24 months) vs. 13 months (95% CI, 10-16 months), P0.05]; the 6-month, 1-year, and 2- year survival rates were 96.6%, 70.8%, and 44.3% respectively in combination group, and 84.7%, 54.4%, and 14.9% respectively in TACE group. The occurrence rate of serious rashes was 11.1% and that of serious somnolency was 6.7%. Multivariate Cox analysis showed that the times of TACE was an independent prognostic factor of HCC. CONCLUSIONS: Compared with TACE alone, the combination of TACE and thalidomide can obviously postpone disease progression and prolong survival of HCC patients. The times of TACE is a prognostic factor of HCC after TACE.
【CateGory Index】: R735.7
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【References】
Chinese Journal Full-text Database 9 Hits
1 ;Combination of TACE with molecularly targeted agent in management of advanced HCC[J];International Journal of Medical Radiology;2009-04
2 Du-Jun Bian,En-Hua Xiao,Dong-Xu Hu,Xiang-Yu Chen,Wei-Jun Situ,Shu-Wen Yuan,Jian-Ling Sun,Li-Ping YangDepartment of Radiology,The Second Xiangya Hospital,Central South University,Changsha,Hunan 410011,P.R.China;Magnetic resonance spectroscopy on hepatocellular carcinoma after transcatheter arterial chemoembolization[J];Chinese Journal of Cancer;2010-02
3 LIN Hai-lan1*,HAO Ming-zhi1,SHEN You-hong2,ZHENG Jian-xiong1,TANG Lin-na2,YAN Ruo-yuan2,CHEN Jing2,WU Zhou-gui2,CHEN Qi-zhong1(1.Department of Interventional Radiology,2.Department of Ultrasound,Fujian Provincial Tumor Hospital,Fuzhou 350014,China);Efficacy of percutaneous ethanol injection in the adjuvant treatment of hepatocellular carcinoma after TACE[J];Chinese Journal of Interventional Imaging and Therapy;2008-05
4 Xu Jinfa,Pan Ming,Chen Qian,Bao Yu,Hua Gaoyan,Tong Zhou(Department of Oncology,Chizhou People's Hospital,Chizhou 247000,China);The Observation of Therapy of Thalidomide Combined with Gemcitabine and Oxaliplatin in the Treatment of Advanced Intrahepatic Cholangiocarcinoma[J];Journal of Basic and Clinical Oncology;2010-05
5 YU Ting,YU Qian,OU Xi-long,CAO Da-zhong,SUN Wei-hao(Department of Gastroenterology,Zhongda Hospital,Southeast University,Nanjing 210009,China);Analysis of factors related to severe hepatic dysfunction after transcatheter arterial chemoembolization in patients with primary hepatic carcinoma[J];Modern Medical Journal;2009-01
6 SHI Ming,CHEN Ji’an,LIN Xiaojun,CHEN Minshan,GUO Rongping,LI Shengping,LI JinqingDepartment of Hepatobiliary Oncology,Cancer Center of Sun Yat-sen University,Guangzhou 510060,China;Prospective Randomized Controlled Study of Transarterial Chemoembolization with Doxorubicin versus Doxorubicin/Lobaplatin/Mitomycin Combination for Unresectable Hepatocellular Carcinoma[J];Chinese Journal of Clinical Oncology;2009-01
7 LU Guangping,PAN Jiqun,YU Zhijian,et al.Department of Oncology,Affiliated Dongtai Hospital,Nantong University,Dongtai 224200,CHINA;A study on the mechanism of thalidomide against HCC cell line SMMC7721[J];Jiangsu Medical Journal;2010-04
8 LI Jing-dong,PENG Yong,DAI Yi,et al(Department of General Surgery,The Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,China);Clinical effects of Huaier and transarterial chemoembolization (TACE) in treatment of advanced hepatocellular carcinoma[J];Medical Journal of West China;2010-03
9 ;肿瘤抗血管生成靶向治疗[J];Chinese Journal of Practical Surgery;2010-07
【Citations】
Chinese Journal Full-text Database 3 Hits
1 Zhai Yu, Lu Zhan-Jun Department of Laboratory Animal, Hebei Medical University, Shijiazhuang,Hebei,050017, P.R.China;Effect of Thalidomide on Tumor Growth in Mouse Hepatoma H22 Model[J];Chinese Journal of Cancer;2003-12
2 DING Gang, LIN Jun hua, LI Guo an,et al (Department of Traditional Chinese Medicine Cancer Hospital of Fudan University, Shanghai 200032);The study of serum vascular endothelial growth factor (VEGF) in the course of transcatheter arterial embolization of hepatocellular carcinoma[J];China Oncology;2003-02
3 Zhong-Lin Zhang, Zhi-Su Liu, Quan Sun, Department of General Surgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, Hubei Province, China;Effects of thalidomide on angiogenesis and tumor growth and metastasis of human hepatocellular carcinoma in nude mice[J];世界胃肠病学杂志(英文版);2005-02
【Co-citations】
Chinese Journal Full-text Database 10 Hits
1 YANG Yi-ming1, DU Gang-jun2, LIN Hai-hong21Department of Oncology, First Affiliated Hospital, 2College of Pharmacy, Henan University, Kaifeng 475001, China;Experimental study of thalidomide for treatment of murine hepatocellular carcinoma[J];Journal of First Military Medical University;2005-08
2 Du Zhi-quan,Pan guang,Xu Cheng-ping1,Liu Zhao-feng Department of Radiology,Kunshan No.2 Hospital,Kunshan 215300;Application of Microcatheter in Interventional Therapy of Hepatic Cell Carcinoma[J];Contemporary Medicine;2009-35
3 WANG Yu,Lian Fan,LI Jia-ping,,LI He-ping,,Chen Wei,YANG Jian-yong.Department of Interventional Radiology,the First Affiliated Hospital of Sun Yat-sen University.Guangzhou 510080,P.R.China.;Evaluation of hepatic blood flow alteration in Celecoib combined with TAE treated liver vx2 tumor rabbits[J];Contemporary Medicine;2009-35
4 Zheng Weisheng1,Chen Qiang2,Ye Yunbin2,Lin Hailan3,Hao Mingzhi3,Yu Wenchang3,Zhang Kongzhi3,Chen Qizhong3(1.Department of Medical Oncology,the 180th Hospital of PLA,Quanzhou 362000,China;2.Fujian Provincial Tumor Hospital & Institute,Fuzhou 350014,China;3.Department of Invasive Technology,Fujian Provincial Tumor Hospital,Fuzhou 350014,China);The Changes of Cellular Immunity Function After Treatment of Thalidomide Combined with TACE for HCC[J];Journal of Basic and Clinical Oncology;2007-02
5 KONG Wei-dong,CAO Jian-min,LI Cheng-lang,XU Jian,GAO Da-zhi,LU Guang-ming(Department of Medical Imaging,Nanjing General Hospital of Nanjing Military Command,PLA,Nanjing 210002,Jiangsu,China);Effect of transcatheter arterial chemoembolization with low or conventional dosage on the fibrosis and prognosis in patients with hepatocellular carcinoma[J];Journal of Medical Postgraduates;2007-09
6 CHEN Qian-li, YE Qiang, GU Wei-zhong, ZHANG Jia-xin, TONG Qian-gang, XI Shun-fa. Department of Radiology, Punan Hospital, Shanghai 200125, China;Evaluation of transcatheter arterial chemoembolization combined with radiofrequency capacitive heating on clinical therapeutic effect of metastatic hepatic carcinoma[J];Journal of Interventional Radiology;2006-07
7 OUYANGYong. Department. of Interventional Radiology, Inner Mongolia Autonomous Region’s Hospital, Huhhot 010017, China;The development course and current status of transcatheter arterial infusion and embolization in China[J];Journal of Interventional Radiology;2008-12
8 LI Jia-kai,ZHANG Jing,YU Miao,ZHANG Jin-shan,YANG Li,XIAO Yue-yong.Department of Radiology,the General Hospital of PLA,Beijing 100853,China;Hepatic arterial chemoembolization via a coaxial microcatheter combined with radiofrequency ablation for the treatment of primary hepatocellular carcinoma[J];Journal of Interventional Radiology;2009-05
9 LIN Hai-lan1*,HAO Ming-zhi1,ZHENG Wei-sheng2,YE Yun-bin1,CHEN Qi-zhong1,CHEN Jian-bin1,ZHENG Jian-xiong1 (1.Department of Interventional Radiology,Fujian Provincial Tumor Hospital,Fuzhou,350014,China;2.Department of Medical Oncology,PLA 180th Hospital,Quan zhou,362000,China);The changes of vascular endothelial growth factor after treatment of thalidomide combined with TACE for HCC[J];Chinese Journal of Interventional Imaging and Therapy;2007-06
10 LIN Hai-lan1*,HAO Ming-zhi1,SHEN You-hong2,ZHENG Jian-xiong1,TANG Lin-na2,YAN Ruo-yuan2,CHEN Jing2,WU Zhou-gui2,CHEN Qi-zhong1(1.Department of Interventional Radiology,2.Department of Ultrasound,Fujian Provincial Tumor Hospital,Fuzhou 350014,China);Efficacy of percutaneous ethanol injection in the adjuvant treatment of hepatocellular carcinoma after TACE[J];Chinese Journal of Interventional Imaging and Therapy;2008-05
China Proceedings of conference Full-text Database 1 Hits
1 Department of Oncology. Traditional Chinese Medicine Hospital of Guangdong Guangzhou XU Kai, ZENG Pu-hua;The Signification of Anti-vascular Growth after TACE of Primary Hepatic Carcinoma——The Primary Discussion about TCM Anti-vascularGrowth Thoughts and Methods[A];[C];2006
【Co-references】
Chinese Journal Full-text Database 10 Hits
1 XIAO En-hua, LI Jin-qing, ZHANG Ya-qi, et al. (Department of Liver and Bladder, Cancer Center, Sun Yat-sen University of Medical Sciences, Guangzhou 510060, P. R. China);Relationship between P-glycoprotein and metastatic potential in hepatocellular carcinoma[J];CHINESE JOURNAL OF CANCER;2000-06
2 Zhai Yu, Lu Zhan-Jun Department of Laboratory Animal, Hebei Medical University, Shijiazhuang,Hebei,050017, P.R.China;Effect of Thalidomide on Tumor Growth in Mouse Hepatoma H22 Model[J];Chinese Journal of Cancer;2003-12
3 Chen Xiao Ming, Luo Peng Fei, Lin Hua Huan, Zhou Ze Jian, Shao Pei Jian, Fu Li, Li Wei Ke Department of Oncology Intervention, Cancer Center,Guangdong Provincial Peoples Hospital, Guangzhou,Guangdong,510080, P.R.China;Long-term Result of Combination of Transcatheter Arterial Chemoembolization and Percutaneous Ethanol Injection for Treatment of Hepatocellular carcinoma[J];Chinese Journal of Cancer;2004-07
4 CHEN Tao, CHU Zhong-Hua, LIU Jian-Ping, WANG Jie, ZHAO Hai-Yan, OU Qing-Jia Department of General Surgery, The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, 510120, P. R. China;Application of Adenosine Triphosphate Tumor Chemosensitive Assay System to Individual Chemotherapy for Hepatocellular Carcinoma[J];Chinese Journal of Cancer;2005-08
5 CHEN Xiao-ming LUO Peng-fei HU Jing-qin SHAO Pei-jian ZHOU Zhejian FU Li TANG Yi YU Yan-xin(Intervenenlional Department of Radiology,Poople,s Hospital of Guangdong ProvincE, Guanzhou 510080 );DELAYED ADVERSE REACTION OF LIVER AFER LIPIODOL-TRANSCATHETR ARTERIAL CHEMoEMBOLIZETION(Lp-TAE)FOR THE TREATMBNT OF HEpATOCELLULAR CARCINOMA[J];CHINESE JOURNAL OF CANCER;1994-01
6 SUN PING,ZHANG LIANG-MING,SUN DENG-JUN,et al(Department of Oncology,Yantai Yuhuangding Hospital,Yantai 264000,China);EFFECTS OF THALIDOMIDE ON PROLIFERATION OF HUMAN HEPATOMA SMMC-7721 CELLS IN VITRO[J];Acta Academiae Medicinae Qingdao Universitatis;2009-05
7 FANG Weigang △, LI Hongmei, KONG Lingling, NIU Guilian, GAO Qing, ZHOU Kexiang,ZHENG Jie, WU Bingquan (Department of Pathology, Peking University School of Basic Medical Sciences,Beijing 100083,China);Role of matrix metalloproteinases (MMPs) in tumor invasion and metastasis: serial studies on MMPs and TIMPs[J];Journal of Peking University(Health Sciences);2003-04
8 LUO Hong-ying,WANG Hai-cheng,FENG De-yun,et al.Department of Pathology, Chenzhou Medical College, Chenzhou 423000,China;Expression of Vascular Endothelial Growth Factor and nm23 Proteins and Microvessel Density in Hepatocellular Carcinoma and Their Relation With Metastasis[J];Journal of Chinese Physician;2003-06
9 JIANG Dao-rong,YAO Deng-fu, ZHU Young, et al. Affiliated Hospital, Nantong Medical College, Nantong 226001, China;VEGF Expression and its Clinical Significance in Human Liver Cancer Specimens[J];Journal of Chinese Physician;2004-02
10 LIU Cheng Li 1, DOU Ke Feng 1,LI Bing 2 Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710033, China, 2Department of Sanatorium,Air Force Donghu Sanatoriums,Wuhan 430072;Expression and significance of vascular endothelial growth factor and its receptors in hepatocellular carcinoma cell lines[J];JOURNAL OF THE FOURTH MILITARY MEDICAL UNIVERSITY;2000-06
【Secondary References】
Chinese Journal Full-text Database 9 Hits
1 ZHU Yu sheng, WU Lin lin,YAN Zhi ping Department of Radiology,Ma An Shan Seventeen Ye Hospital,Ma An Shan 243000, An Hui Sheng, Department of Radiology,Shang Hai Zhong Shan Hospital, Shang Hai, 200032 China;Progresses in Research of Interventional treatment of hepatocellular carcinoma domestic[J];Contemporary Medicine;2009-23
2 YANG Liu-qing,QIN Shu-kui.Tumor Center of PLA,81 Hospital of PLA,Nanjing 210002,China;Progression of lobaplatin as the third generation platinum drug[J];Chinese Clinical Oncology;2009-12
3 YANG Chao-xu,QIN Shu-kui.PLA Cancer Center,81st Hospital of PLA,Nanjing 210002,China;Clinical study progression of oxaliplatin for primary hepatic carcinoma[J];Chinese Clinical Oncology;2010-09
4 WEI Yong,TU Rong, CHEN Zhongming,et al.Radiology Department of Affiliated Hospital of Hainan Medical College,Cancer Institute of Hainan Medical College,Haikou,Hainan Province 570102,P.R.China;Hepatic Functional Reserve and Prognosis after Liver Interventional Therapy:Evaluation by CT Grading of Liver Cirrhosis[J];Journal of Clinical Radiology;2010-12
5 TANG Ying1,JIANG Guo-rong2(1.Nanjing University of Chinese Medicine,Nanjing 210029,Jiangsu,China;2.Suzhou Hospital of Traditional Chinese Medicine Affiliated to Nanjing University of Chinese Medicine,Suzhou 215003,Jiangsu,China);Clinical Application of Yiqi Chinese Medicine in Interventional Chemotherapy of Primary Hepatic Carcinoma[J];Journal of Liaoning University of Traditional Chinese Medicine;2011-02
6 XU Lu, FENG Long, JIANG Wei-min, LI Ling.Department of Oncology, Second Affiliated Hospital, Nanchang University, Nanchang 330006, China;Intratumoral injection of lipiodol pingyangmycin combined with thalidomide in treatment of recurrent advanced liver cancer[J];The Journal of Practical Medicine;2010-11
7 LI Ya-long,MA Ren-kai.(The Second People's Hospital of Bai Yun District,Guangzhou 510450,China);Arteria Hepatica Involved in Chemotherapy Embolism with Conbined Treatment of Chinese and Western Medicine to Advanced Stage Liver Cancer[J];Medical Recapitulate;2009-13
8 LI Huai-bo,ZHANG Zhen-Qing,DAI Han-bi,ZHUANG Xiang-rong,YE Feng(Department of Radiology,Xiamen Zhongshan Hospital,Xiamen University,Xiamen 361004,China);Comprehensive analysis of long-term survival of liver neoplasms patients after interventional therapy[J];Chinese Journal of Medical Imaging Technology;2009-12
9 WANG Yong-zhong.(Department of Radiology,The Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China);ENDOSTAR INFUSION COMBINED WITH INTERVENTIONAL CHEMOTHERAPY AND EMBOLIZATION INTERVENTIONAL THERAPY IN TREATMENT OF ADVANCED LIVER CANCER[J];Modern Preventive Medicine;2011-02
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved